$TDOC - $VKTX - On our trading list with news today or analyst comments with our opinion & trade ideas. Teladoc has their price target raised by Piper. Viking Therapeutics initiated with an Outperform rating by BMO Capital.Teladoc price target raised to $220 from $212 at Piper SandlerPiper Sandler analyst Sean Wieland raised the firm's price target on Teladoc to $220 from $212 and keeps an Overweight rating on the shares. The Centers for Medicare and Medicaid Services on Tuesday published new network adequacy rules for Medicare Advantage that establish the incentives necessary to drive an inflection in telemedicine in 2021, Wieland tells investors in a research note. This is the agency's second attempt to advance telemedicine growth in Medicare Advantage and it represents a "considerably stronger and more complete approach" than the first, says the analyst. Wieland believes the new network adequacy rules introduce "real, structural catalysts" for telemedicine growth in Medicare Advantage starting next year. The analyst thinks national, multi-specialty telemedicine vendors will dominate the Medicare Advantage market, and he views Teladoc as best positioned among them.Our Take: Been a big winner for our group, but does have a good bit of volatility! Buy the dips/sell the peaks kind of stock. Options could be played as well.Viking Therapeutics initiated with an Outperform at BMO CapitalBMO Capital analyst Matthew Luchini initiated coverage of Viking Therapeutics with an Outperform rating and $14 price target. Viking's lead drug, VK2809, has shown "early but encouraging" proof-of-concept and presents an attractive potential option for the treatment of non-alcoholic steatohepatitis, or NASH, Luchini tells investors. He sees the drug having the potential for "best-in-class" reduction in liver fat along with a positive impact on markers of cardiovascular disease, the analyst added.Our Take: Nice little biotech with some good potential. Buy-writes and selling naked puts could be a good way to play this. $VKTX, Viking Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Give Try2BeFunded a try! .